ALPN News and Press, Alpine Immune Sciences Inc. From 06/15/20

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting II, taking place June...

Alpine Immune Sciences ( ALPN +5.4% ) presents updated results from its phase 1 study of ALPN-101, dual CD28/ICOS costimulation antagonist for autoimmune and inflammatory diseases. More news on: Alpine Immune Sciences, Inc., Healthcare stocks news, Read more ...

-- ALPN-101 was well tolerated and exhibited potent pharmacodynamic activity, enabling Phase 2 development -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory dise...

First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developin...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR 2020 E-Congress, taking place virtu...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare...

Alpine Immune Sciences (NASDAQ: ALPN ): Q1 GAAP EPS of -$0.30 beats by $0.17 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Granted FDA Orphan Drug Designations for ALPN-101 in Acute GVHD - - BALANCE and NEON-1 Trials Open for Enrollment - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/in...

- NEON-1 is now open for enrollment for patients with advanced malignancies - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today presented the des...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...